Company Overview of Neurimmune Holding AG
Neurimmune Holding AG, a biotechnology company, engages in the development and commercialization of human antibody therapeutics for the treatment and prevention of common human diseases. The company focuses on protein aggregation diseases; and neurodegenerative disorders, such as Alzheimer’s disease. Its pipeline comprises programs in neurodegeneration, including Alzheimer's and Parkinson's diseases, tauopathies, and amyotrophic lateral sclerosis or Lou Gehrig's disease. The company develops human monoclonal antibodies as therapeutics based on its Reverse Translational Medicine technology platform. Neurimmune Holding AG was founded in 2006 and is based in Schlieren, Switzerland.
Founded in 2006
41 44 755 46 46
41 44 755 46 47
Key Executives for Neurimmune Holding AG
Neurimmune Holding AG Key Developments
Similar Private Companies By Industry
|BOWS Pharmaceuticals AG||Europe|
|Celgene International Sárl||Europe|
|CELLnTEC Advanced Cell Systems AG||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact Neurimmune Holding AG, please visit www.neurimmune.com. Company data is provided by Capital IQ. Please use this form to report any data issues.